Opdivo (nivolumab) - Ono Pharmaceutical, BMS
Opdivo Qvantig (nivolumab and hyaluronidase-nvhy) - BMS, Ono Pharmaceutical
A Study of ONO-4538HSC in Pediatric Patients With Malignant Solid Tumors and in Patients With Epithelioid Sarcoma. (clinicaltrials.gov) - Sep 9, 2026 - P1/2 | N=50 | Recruiting | Sponsor: Ono Pharmaceutical Co., Ltd. | Not yet recruiting ➔ Recruiting 
Enrollment open • Oncology • Pediatrics • Sarcoma • Soft Tissue Sarcoma • Solid Tumor
http://clinicaltrials.gov/ct2/show/NCT07734116
 
Sep 9, 2026
 
Prev Next